Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)-Reference-Cited by-同舟云学术

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

Published:2015-09-26 Issue:12 Volume:94 Page:1981-1989
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

de Witte Theo,Suciu Stefan,Meert Liv,Halkes Constantijn,Selleslag Dominik,Bron Dominique,Amadori Sergio,Willemze Roel,Muus Petra,Baron Frédéric

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-015-2486-9.pdf

Reference32 articles.

1. Stone RM (2009) How I, treat patients with myelodysplastic syndromes. Blood 113(25):6296–6303

2. Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A et al (2015) Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. Ann Hematol 94(1):23–34

3. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C et al (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122(17):2943–2964

4. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77(4):497–501

5. Hast R, Hellstrom-Lindberg E, Ohm L, Bjorkholm M, Celsing F, Dahl IM et al (2003) No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leuk Off J Leuk Soc Am Leuk Res Fund UK 17(9):1827–1833

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Bcl‐2 inhibition in myelodysplastic syndromes;International Journal of Cancer;2022-12-08

2. Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay;Leukemia Research;2022-01

3. Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin;Cancers;2021-09-11

4. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations;Science Advances;2021-02-19

5. Immunotherapies for Myelodysplastic Syndromes: Current State and Future Developments;Erciyes Medical Journal;2021